Clinical study begins in Japan for Moderna's COVID-19 vaccine

Takeda Pharmaceutical Co. said Thursday it has begun clinical trials in Japan of a COVID-19 vaccine candidate by U.S. biotech firm Moderna Inc. with an eye to distributing it in the first half of this year. Takeda, which is undertaking clinical trials and distribution in Japan of the U.S. company’s vaccine known as mRNA-1273, will target 200 adults in the study. The drugmaker is planning to provide 50 million doses, or enough for 25 million people after obtaining regulatory approval. Each person would need two doses of the COVID-19 vaccine. Japan is struggling to cope with a resurgence in coro…

Read More

HEDGE accordingly